Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Dicks Sporting Goods Inc (DKS) vs Mesoblast Limited (MESO) Price & Performance

Dicks Sporting Goods IncTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Dicks Sporting Goods Inc vs Mesoblast Limited — how do they compare? Dicks Sporting Goods Inc trades at $211.39 (market cap $18.92B), while Mesoblast Limited trades at $17.61 (market cap $2.12B). The key difference: Dicks Sporting Goods Inc is far larger — about 8.9× Mesoblast Limited's market cap, and Dicks Sporting Goods Inc pays a 2.37% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.

DKSMESO
Market Cap
$18.92B$2.12B
Sector
Consumer CyclicalTechnology
52-Week High
$239.17$20.96
52-Week Low
$187.78$10.96
Enterprise Value
$25.71B$2.13B
Dividend Yield
2.37%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Dicks Sporting Goods Inc

Dick's Sporting Goods (DKS) trades at $216.10, down 0.86% with a bearish technical outlook despite strong fundamentals. The company reported consistent earnings beats, with Q1 2026 EPS of $2.90 exceeding expectations, and maintains solid profitability with a 4.71% net margin. Recent developments include the launch of ScoreCard+ loyalty program and Lids partnership expansion. Analyst consensus remains strongly bullish with a $261 price target, though legal scrutiny over fiduciary duties presents near-term headwinds.

DKS offers attractive valuation with a P/E of 20.58 and P/S of 0.96, trading below analyst targets. Growth catalysts include market share gains and strategic partnerships, but risks involve competitive pressures and potential legal overhangs. The stock's current dip may present a buying opportunity for long-term investors given fundamental strength and institutional support.

Mesoblast Limited

MESO trades at $16.22, up 5.05% today, with a bullish technical outlook from moving averages but mixed oscillators. The company shows strong gross margins of 80.52% but remains unprofitable with a net income margin of -144.33%. Recent news highlights commercial progress, including Ryoncil revenue of $36 million in Q4 2026 and pivotal Phase 3 trial milestones for chronic low back pain.

The outlook is cautiously optimistic, driven by FDA-approved Ryoncil's revenue growth and pipeline advancements, but high valuation (P/S 30.52) and persistent losses pose risks. Analyst consensus leans buy (45.46%), yet investors face volatility from clinical trial outcomes and cash burn concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Dicks Sporting Goods Inc

Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.

Read more on DKS

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO